Sunitinib maleate

Nature Reviews Drug Discovery

Volumn 5, Issue 4, 2006, Pages 279-280

  Atkins, Michael ^a   Jones, Carole A ^b   Kirkpatrick, Peter ^c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b IQVIA   (United States)

^c Nature Reviews Drug Discovery ^*

Author keywords

[No Author keywords available]

Indexed keywords

AG 013736; ALPHA INTERFERON; BCR ABL PROTEIN; BEVACIZUMAB; IMATINIB; INTERLEUKIN 2; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MUCOSA INFLAMMATION; NOTE; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG DESIGN; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; KIDNEY NEOPLASMS; PYRROLES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 33645473155     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2012     Document Type: Note

References (13)

1. Krause, D. S. & Van Ettten, R. A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353, 172-187 (2005).
2. Cohen, H. T. & McGovern, F. J. Renal-cell carcinoma. N. Engl. J. Med. 353, 2477-2490 (2005).
3. Atkins, M. B. et al. Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin.Cancer Res. 9, 6277S-6281S (2004).
4. Bergers, G. et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111, 1287-1295 (2003).
5. Sun, L. et al. Discovery of
6. Mendel, D. B. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors. Clin. Cancer Res. 9, 327-337 (2003).
7. Demetri, G. D. Identification and treatment of chemoresistant inoperable or metastatic GIST: Experience with the selective tyrosine kinase inhibitor imatinib mesylate. Eur. J. Cancer 38, S52-S59 (2002).
8. FDA labelling information [online], (2006).
9. Motzer, R. J. et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 16-24 (2006).
10. Motzer, R. J. et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. A4508 (2005).
11. Yang, J. C. et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427-434 (2003).
12. Escudier, B. et al. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. A4510 (2005).
13. Rini, B. et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). Proc. Am. Soc. Clin. Oncol. A4509 (2005).